16223-24-8

Usage

Type of Compound

Synthetic chemical compound

Neuroprotective

Exhibits neuroprotective effects in animal models of neurodegenerative diseases

Analgesic

Demonstrates potential analgesic effects in preclinical pain models

Mechanism of Action

Acts as a selective agonist at the sigma-2 receptor

Sigma-2 Receptor Involvement

The sigma-2 receptor is involved in various cellular processes, including cell survival and proliferation

Neurodegenerative Diseases

BU224 has shown neuroprotective effects in animal models of diseases such as Parkinson's and Alzheimer's

Chronic Pain

Potential analgesic effects make it a candidate for developing treatments for chronic pain conditions

Research Significance

BU224 has the potential to be a valuable tool for understanding the sigma-2 receptor and developing novel treatments for neurodegenerative diseases and chronic pain.

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 3342-78-7 2-(2-aminophenyl)acetic acid 
• 857262-24-9 C₂₉H₄₀N₂O₄ 
• 16223-21-5 N-(1-Benzyl-piperidin-4-yl)-2-chloro-N-phenyl-acetamide 
• 100-52-7 benzaldehyde 
• 16223-25-9 1,3-dihydro-1-(piperidin-4-yl)-(2H)-indol-2-one 
• 382150-69-8 di-tert-butyl 2-(2-nitrophenyl)malonate 
• 1493-27-2 ortho-nitrofluorobenzene 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 55116-09-1 2-bromophenylacetyl chloride 

Downstream Products

• 1240702-12-8 1-(1-benzylpiperidin-4-yl)-3,3-dimethylindolin-2-one 

Relevant academic research and scientific papers

A novel synthesis of N-(piperidin-4-yl)-1,3-dihydroindol-2-one via an intramolecular Pd-catalyzed amination

A novel efficient synthetic route to the pharmaceutical key intermediate N-(piperidin-4-yl)-1,3-dihydroindol-2-one is described. The key step involves a high-yielding intramolecular palladium-catalyzed amination reaction using Buchwald's X-Phos ligand und

Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.

The nociceptin receptor (NOP) and its endogenous agonist, nociceptin/orphanin FQ (N/OFQ), members of the opioid receptor and peptide families respectively, modulate the pharmacological effects of classical opioids, particularly opioid-induced reward and nociception. We hypothesized that compounds containing both NOP and opioid receptor activity in a single molecule may have useful pharmacological profiles as non-addicting analgesics or as drug abuse medications. We report here our forays into the structure-activity relationships for discovering 'bifunctional' NOP-mu opioid receptor (MOP) ligands, starting from our NOP-selective scaffolds. This initial SAR suggests pharmacophoric elements that may be modified to modulate/increase opioid affinity, while maintaining high affinity for the NOP receptor, to result in potent bifunctional small-molecule NOP/MOP ligands.

Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors

A series of piperidine amide inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) were identified via modifications of the HTS hit compound 1. The synthesis, in vitro biological evaluation, and structure-activity relationship of these co

AGONIST AND ANTAGONIST LIGANDS OF THE NOCICEPTIN RECEPTOR

Novel piperidyl indolinone compounds are provided that are useful as agonist and antagonist ligands of the nociceptin receptor. The compounds are useful to treat a variety of disorders, and are particularly useful as analgesics.